stockrow
Monday 9 November 2026
Export DRUG’s income statement to Excel — free account
Bright Minds Biosciences Inc.
DRUG- EPS
- +67.9%
- Free cash flow
- −124.6%
- Total debt
- −84.7%
Quarter to June 2026, against a year earlier
23.00
2.30
+11.11%
Follow DRUG
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | 0 | (7) | (7) | (12) | (5) | (2) | (9) | (18) | +129.6% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | 0 | 0 | (7) | (12) | (5) | (2) | (9) | (18) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.05) | (0.50) | (3.80) | (4.75) | (1.47) | (0.48) | (1.27) | (2.08) | +74.2% | ||||||
| Cash flow | — | — | — | (0.02) | (0.30) | (3.23) | (4.31) | (1.40) | (0.32) | (0.90) | (1.81) | +82.1% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.02) | (0.30) | (3.23) | (4.31) | (1.40) | (0.32) | (0.90) | (1.81) | +82.1% | ||||||
| Book value | — | — | — | 0.08 | 0.00 | 8.56 | 3.34 | 1.32 | 0.94 | 8.53 | 22.62 | +120.0% | ||||||
| Shares, m | — | — | — | 1 | 1 | 2 | 2 | 4 | 4 | 7 | 9 | +32.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 0 | 0 | (6) | (11) | (5) | (1) | (6) | (18) | +140.9% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | 0 | 0 | (6) | (11) | (5) | (1) | (6) | (18) | +140.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | 15 | 15 | 8 | 5 | 4 | 59 | 222 | +248.3% | |||||
| Net debt | — | — | — | 0 | (16) | (16) | (9) | (5) | (4) | (59) | (222) | +215.0% | ||||||
| Shareholders’ equity | — | — | — | 0 | 15 | 15 | 8 | 5 | 4 | 59 | 222 | +191.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (95.98) | (43.17) | (43.17) | (92.53) | (75.07) | (42.96) | (26.97) | (13.52) | +69.0 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | (18.59) | 93.93 | (169.76) | (99.25) | (83.16) | (45.96) | (27.88) | (13.64) | (9.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 25 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Bright Minds Biosciences Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SLGL Sol-Gel Technologies Ltd. | $206.3M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| RNAC Cartesian Therapeutics, Inc. | $205.1M | — (loss-making) | — (loss-making) | −92.91% (below 0%: shrinking) | −7.84% (below 0%: shrinking) | −6.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| DRUG Bright Minds Biosciences Inc. | $204.2M | — (loss-making) | — | — | n/m | −124.63% (below 0%: shrinking) | 0.00% | 0.00% | |
| PLX Protalix BioTherapeutics, Inc. | $202.2M | 10.5× | 10.6× | +27.07% (above 0%: growing) | +2,280.95% (above 0%: growing) | −94.09% (below 0%: shrinking) | 60.99% | 23.48% | Compare |
| PALI Palisade Bio, Inc. | $202.2M | 1.8× | — (loss-making) | +19,900.00% (above 0%: growing) | n/m | −318.44% (below 0%: shrinking) | 100.00% | (2,339.60%) | Compare |
| ARTV Artiva Biotherapeutics, Inc. | $201.9M | — (loss-making) | — (loss-making) | — | n/m | +13.60% (above 0%: growing) | 100.00% | 0.00% | Compare |
| IKT Inhibikase Therapeutics, Inc. | $200.9M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −123.23% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ELDN Eledon Pharmaceuticals, Inc. | $199.9M | — (loss-making) | — | — | n/m | −28.02% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IFRX InflaRx N.V. | $199.7M | — (loss-making) | — (loss-making) | −128.93% (below 0%: shrinking) | n/m | +59.76% (above 0%: growing) | 14,029.95% | 0.00% | Compare |
| Median of peers | $202.0M | — | — | −94.74% | — | −18.39% | 100.00% | 0.00% |